Vaxcyte pneumococcal vaccine hits primary endpoints in Phase 3 clinical trial
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Vaxcyte announced that its pneumococcal vaccine successfully met its primary endpoints in a Phase 3 clinical trial, positioning the product to compete directly with established offerings from Pfizer and Merck.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu